Compare Biogen Inc (BIIB) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Twilio Inc — how do they compare? Biogen Inc trades at $194.08 (market cap $28.34B), while Twilio Inc trades at $217.15 (market cap $33.06B). The key difference: Twilio Inc is the larger of the two by market cap, and Twilio Inc is trading nearer its 52-week high, Biogen Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | TWLO | |
|---|---|---|
Market Cap | $28.34B | $33.06B |
Sector | Health | Technology |
52-Week High | $216.63 | $236.64 |
52-Week Low | $122.68 | $92.44 |
Enterprise Value | $30.62B | $31.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Twilio (TWLO) trades at $218.24, up 1.72% today, showing strong momentum after recent earnings beats. The stock is in a bullish technical trend with support at $212 and resistance at $223. Revenue grew to $5.07B in 2025, with net income turning positive at $33.83M, signaling a successful turnaround. Analyst sentiment is overwhelmingly positive, with 77% recommending Buy and a consensus price target of $215.14. Operating cash flow reached $1.0B, reflecting improved financial health.
Outlook: Twilio's AI-driven communication tools and margin expansion under CEO Khozema Shipchandler support growth, but high valuation multiples (P/E 330.67) pose risks. Competition and execution challenges remain key concerns. The stock offers upside if earnings momentum continues, yet volatility near 52-week highs warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
